Imphal News Flash

Global Adalimumab, Infliximab and Etanercept Biosimilars Market Value Expected To Reach $7.50 Billion By 2023

 Breaking News
  • No posts were found

Global Adalimumab, Infliximab and Etanercept Biosimilars Market Value Expected To Reach $7.50 Billion By 2023

October 30
22:01 2020
Global Adalimumab, Infliximab and Etanercept Biosimilars Market Value Expected To Reach $7.50 Billion By 2023

Adalimumab, Infliximab And Etanercept Biosimilars Global Market Report 2020-30: COVID-19 Growth And Change

Zydus Cadila Is One Of The Largest Players In The Adalimumab, Infliximab and Etanercept Biosimilars Market, According To The Business Research Company’s Adalimumab, Infliximab And Etanercept Biosimilars Global Market Report 2020-30: COVID-19 Growth And Change

(Companies Covered: Zydus Cadila, Sandoz (Novartis), Samsung Bioepis, Abbvie, Amgen, Boehringer Ingelheim, Pfizer, Celltrion, Mylan, Hetero Drugs Ltd, Glenmark pharmaceuticals, Cipla Ltd, Emcure Pharmaceuticals Ltd.)

The global adalimumab, infliximab, and etanercept market is expected to grow from $2.2 billion in 2019 to $2.27 billion in 2020 at a compound annual growth rate of 3.24%. The slow growth is mainly due to the COVID-19 outbreak that has led to restrictive containment measures involving social distancing, remote working, and the closure of industries and other commercial activities resulting in operational challenges. The entire supply chain has been disrupted, impacting the market negatively. The market is then expected to recover and reach $7.50 billion in 2023 at a compound annual growth rate of 48.94%.

Read More On The Global Adalimumab, Infliximab and Etanercept Biosimilars Market Report At – https://www.thebusinessresearchcompany.com/report/adalimumab-infliximab-and-etanercept-biosimilars-global-market-report-2020-30-covid-19-growth-and-change

The adalimumab, infliximab and etanercept biosimilars market consists of sales of adalimumab, infliximab and etanercept biosimilar drugs by the companies that manufacture these biosimilars. Adalimumab, infliximab and etanercept biosimilar molecules are bioequivalent to original reference molecules such as Humira, Remicade and Enbrel, respectively.

Global Adalimumab, Infliximab and Etanercept Biosimilars Market Segmentation –
1) By Product: Adalimumab biosimilars (Exemptia, Mabura, Hyrimoz, Hadlima, Abrilada, others), Infliximab biosimilars (Inflectra, Renflexis, Ixifi, Avsola), Cipleumab (Erelzi, Eticovo).
2) By Application: Crohn’s disease, Psoriatic arthritis, Rheumatoid arthritis, Ulcerative colitis, Ankylosing spondylitis, Plaque psoriasis, Others.

Global Adalimumab, Infliximab and Etanercept Biosimilars Market Driver –
The brand versions of biosimilar drugs are of high costs, which are now being replaced with biosimilar versions upon their patent’s expiry. The cost of branded biologic drugs almost doubled in recent years.

Request For A Sample Of The Global Adalimumab, Infliximab and Etanercept Biosimilars Market Report At – https://www.thebusinessresearchcompany.com/sample.aspx?id=3473&type=smp

Few Points From The Global Adalimumab, Infliximab and Etanercept Biosimilars Market TOC
1. Executive Summary
2. Adalimumab, Infliximab And Etanercept Biosimilars Market Characteristics
3. Adalimumab, Infliximab And Etanercept Biosimilars Market Size And Growth
3.1. Global Adalimumab, Infliximab And Etanercept Biosimilars Historic Market, 2015 – 2019, $ Billion
3.1.1. Drivers Of The Market
3.1.2. Restraints On The Market
3.2. Global Adalimumab, Infliximab And Etanercept Biosimilars Forecast Market, 2019 – 2023F, 2025F, 2030F, $ Billion
3.2.1. Drivers Of The Market
3.2.2. Restraints On the Market
4. Adalimumab, Infliximab And Etanercept Biosimilars Market Segmentation
4.1. Global Adalimumab, Infliximab And Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
4.2. Global Adalimumab, Infliximab And Etanercept Biosimilars Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
4.3. Global Adalimumab, Infliximab And Etanercept Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
5. Adalimumab, Infliximab And Etanercept Biosimilars Market Regional And Country Analysis
5.1. Global Adalimumab, Infliximab And Etanercept Biosimilars Market, Split By Region, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
5.2. Global Adalimumab, Infliximab And Etanercept Biosimilars Market, Split By Country, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

Interested to know more about The Business Research Company?
The Business Research Company is a market intelligence firm that excels in company, market, and consumer research. Located globally it has specialist consultants in a wide range of industries including manufacturing, healthcare, financial services, chemicals, and technology.

Media Contact
Company Name: The Business Research Company
Contact Person: Oliver Guirdham
Email: Send Email
Phone: +44 20 7193 0708
Address:
City: London
State: Greater London
Country: United Kingdom
Website: https://www.thebusinessresearchcompany.com/


Warning: count(): Parameter must be an array or an object that implements Countable in /home/indoreonlinejour/imphalnewsflash.in/wp-content/themes/legatus-theme/includes/single/post-tags.php on line 5
Share